Nature Search

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

Here, Heitmann et al. report results from a Phase I/II trial evaluating CoVac-1, a peptide-based T-cell activator, in patients with B-cell deficiency, demonstrating potent induction of SARS-CoV-2-specific T-cell responses along with a favorable safety profile.

Jonas S. Heitmann
Claudia Tandler
Juliane S. Walz
ResearchOpen Access18 Aug 2023
Nature Communications

Volume: 14, P: 1-10
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity

A phase I open-label trial evaluating the immunogencity, reactogenicity and safety of a peptide-based SARS-CoV-2 vaccine candidate to induce SARS-CoV-2-specific T cell responses.

Jonas S. Heitmann
Tatjana Bilich
Juliane S. Walz
ResearchOpen Access23 Nov 2021
Nature

Volume: 601, P: 617-622
Vector competence of mosquitoes from Europe for Tahyna virus

Patrick Höller
Renke Lühken
Stephanie Jansen
ResearchOpen Access11 Jul 2025
Scientific Reports

Volume: 15, P: 1-7
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

The DNAJB1-PRKACA fusion transcript is the oncogenic driver in fibrolamellar hepatocellular carcinoma, a lethal disease with limited therapeutic options. Here, the authors identify the DNAJB1-PRKACA protein as a source for immunogenic neoepitopes and a potential target of T cell-based immunotherapy.

Jens Bauer
Natalie Köhler
Juliane S. Walz
ResearchOpen Access27 Oct 2022
Nature Communications

Volume: 13, P: 1-16
SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

SARS-CoV-2-specific CD4⁺ and CD8⁺ T cell epitopes are found in both convalescent patients and virus-naive volunteers and are indicative of heterologous recognition shared with seasonal cold viruses.

Annika Nelde
Tatjana Bilich
Juliane S. Walz
Research30 Sept 2020
Nature Immunology

Volume: 22, P: 74-85
TOF_IMS mass spectrometry-based immunopeptidomics refines tumor antigen identification

MS-based immunopeptidomics provides direct evidence for HLA peptide-antigen presentation, which is indispensable for therapeutic use. Here the authors present an ion mobility MS-based immunopeptidome workflow, largely expand benign reference databases and enables next generation tumor antigen discovery.

Naomi Hoenisch Gravel
Annika Nelde
Juliane S. Walz
ResearchOpen Access17 Nov 2023
Nature Communications

Volume: 14, P: 1-12
Photosynthetic light requirement near the theoretical minimum detected in Arctic microalgae

This study shows that photosynthesis in the Arctic Ocean can occur at lower light levels than previously thought. This finding is based on unique measurements made on microalgae underneath sea ice in the high Arctic at the end of the polar night.

Clara J. M. Hoppe
Niels Fuchs
Jonas Wloka
ResearchOpen Access04 Sept 2024
Nature Communications

Volume: 15, P: 1-10
Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity

Serology is an important way to monitor SARS-CoV-2 infection in the population and support vaccine development. Here the authors develop a multiplex immunoassay including spike and nucleocapsid proteins of SARS-CoV-2 and the endemic human coronaviruses with high specificity and sensitivity.

Matthias Becker
Monika Strengert
Nicole Schneiderhan-Marra
ResearchOpen Access19 Feb 2021
Nature Communications

Volume: 12, P: 1-12
Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer

The definition of biomarkers to predict therapy responses to immune-checkpoint inhibitors represent an unmet clinical need. Here the authors provide evidences that platelet-derived PD-L1 could serve as a prognostic and predictive biomarker in patients with non-small cell lung cancer.

Clemens Hinterleitner
Jasmin Strähle
Lars Zender
ResearchOpen Access01 Dec 2021
Nature Communications

Volume: 12, P: 1-16
Comprehensive Mosquito Wing Image Repository for Advancing Research on Geometric Morphometric- and AI-Based Identification

Kristopher Nolte
Eric Agboli
Renke Lühken
ResearchOpen Access29 Apr 2025
Scientific Data

Volume: 12, P: 1-6
NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia

NFAT2 is a transcription factor that has been linked with chronic lymphocytic leukaemia (CLL), but its functions in CLL manifestation are still unclear. Here the authors show, by analysing mouse CLL models and characterising biopsies from CLL patients, that NFAT2 is an important regulator for the anergic phenotype of CLL.

Melanie Märklin
Jonas S. Heitmann
Martin R. Müller
ResearchOpen Access02 Oct 2017
Nature Communications

Volume: 8, P: 1-14
DNAM-1/CD226 is functionally expressed on acute myeloid leukemia (AML) cells and is associated with favorable prognosis

Anna Chashchina
Melanie Märklin
Boris Klimovich
ResearchOpen Access09 Sept 2021
Scientific Reports

Volume: 11, P: 1-12
CD105 (Endoglin) as negative prognostic factor in AML

Joseph Kauer
Karolin Schwartz
Melanie Märklin
ResearchOpen Access04 Dec 2019
Scientific Reports

Volume: 9, P: 1-11
Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody

Sylwia A. Stefańczyk
Ilona Hagelstein
Melanie Märklin
ResearchOpen Access18 Apr 2024
Blood Cancer Journal

Volume: 14, P: 1-10
Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia

Maddalena Marconato
Joseph Kauer
Jonas S. Heitmann
ResearchOpen Access23 Sept 2022
Scientific Reports

Volume: 12, P: 1-10
Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity

N Helbekkmo
S H Sundstrøm
R M Bremnes
ResearchOpen Access26 Jun 2007
British Journal of Cancer

Volume: 97, P: 283-289

Search

Filter By:

Search

Quick links